• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嗅觉功能障碍与阿尔茨海默病病程中的脑淀粉样蛋白沉积和认知功能有关。

Olfactory Dysfunction Is Associated with Cerebral Amyloid Deposition and Cognitive Function in the Trajectory of Alzheimer's Disease.

机构信息

Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

出版信息

Biomolecules. 2023 Aug 31;13(9):1336. doi: 10.3390/biom13091336.

DOI:10.3390/biom13091336
PMID:37759734
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10526796/
Abstract

Olfactory dysfunction is consistently observed in individuals with Alzheimer's disease (AD), but its association with beta-amyloid (Aβ) deposition remains unclear. This study aimed to investigate the relationship among olfactory function, cerebral Aβ deposition, and neuropsychological profiles in individuals with no cognitive impairment (NCI), mild cognitive impairment (MCI), and AD dementia. A total of 164 participants were included, and olfactory function was assessed using the brief smell identification test (B-SIT). Cerebral Aβ deposition was measured using [F]-flutemetamol PET imaging (A-PET). The results show a significant group difference in olfactory function, with the highest impairment observed in the Aβ-positive MCI and AD dementia groups, and the impairment was the lowest in Aβ-negative NCI. Olfactory dysfunction was positively associated with cognitive impairments across multiple domains. Furthermore, individuals with Aβ deposition had lower olfactory function compared to those without Aβ, even within the same neuropsychological stage. The association between olfactory dysfunction and Aβ deposition was observed globally and in specific cortical regions. These findings suggest that olfactory dysfunction is associated with both cognitive function and cerebral Aβ pathology in the trajectory of AD. Olfactory deficits may serve as an additional marker for disease progression and contribute to understanding the underlying mechanisms of AD.

摘要

嗅觉功能障碍在阿尔茨海默病(AD)患者中经常观察到,但它与β-淀粉样蛋白(Aβ)沉积的关系仍不清楚。本研究旨在调查无认知障碍(NCI)、轻度认知障碍(MCI)和 AD 痴呆患者的嗅觉功能、大脑 Aβ沉积与神经心理学特征之间的关系。共纳入 164 名参与者,使用简短嗅觉识别测试(B-SIT)评估嗅觉功能。使用 [F]-flutemetamol PET 成像(A-PET)测量大脑 Aβ 沉积。结果表明,嗅觉功能在组间存在显著差异,Aβ 阳性的 MCI 和 AD 痴呆组的嗅觉功能障碍最严重,而 Aβ 阴性的 NCI 组的嗅觉功能障碍最低。嗅觉功能障碍与多个认知领域的认知障碍呈正相关。此外,与无 Aβ 的个体相比,即使在相同的神经心理学阶段,有 Aβ 沉积的个体的嗅觉功能也较低。嗅觉功能障碍与 Aβ 沉积之间的关联在全脑和特定皮质区域均存在。这些发现表明,嗅觉功能障碍与 AD 轨迹中的认知功能和大脑 Aβ 病理学均有关。嗅觉缺陷可能作为疾病进展的附加标志物,并有助于理解 AD 的潜在机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0a/10526796/e8b086c8d388/biomolecules-13-01336-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0a/10526796/124eb37f29a5/biomolecules-13-01336-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0a/10526796/23b68465103e/biomolecules-13-01336-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0a/10526796/e8cfe8f35e61/biomolecules-13-01336-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0a/10526796/e8b086c8d388/biomolecules-13-01336-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0a/10526796/124eb37f29a5/biomolecules-13-01336-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0a/10526796/23b68465103e/biomolecules-13-01336-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0a/10526796/e8cfe8f35e61/biomolecules-13-01336-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d0a/10526796/e8b086c8d388/biomolecules-13-01336-g004.jpg

相似文献

1
Olfactory Dysfunction Is Associated with Cerebral Amyloid Deposition and Cognitive Function in the Trajectory of Alzheimer's Disease.嗅觉功能障碍与阿尔茨海默病病程中的脑淀粉样蛋白沉积和认知功能有关。
Biomolecules. 2023 Aug 31;13(9):1336. doi: 10.3390/biom13091336.
2
Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.认知障碍患者从记忆门诊连续招募的淀粉样蛋白结合的异质性:评估定量 18F-氟美曲特 PET-CT 在轻度认知障碍与阿尔茨海默病和其他痴呆症鉴别中的效用。
J Alzheimers Dis. 2021;79(2):819-832. doi: 10.3233/JAD-200890.
3
Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.β淀粉样蛋白加权皮质厚度:阿尔茨海默病的一种新型影像生物标志物。
Curr Alzheimer Res. 2015;12(6):563-71. doi: 10.2174/1567205012666150530202124.
4
Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease.糖酵解系统功能障碍可预测阿尔茨海默病中的淀粉样蛋白沉积、神经退行性变和临床进展。
Alzheimers Dement. 2024 May;20(5):3251-3269. doi: 10.1002/alz.13789. Epub 2024 Mar 19.
5
Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease.阿尔茨海默病患者 Tau、Aβ 与皮质厚度和认知的相关性。
Neurology. 2019 Feb 5;92(6):e601-e612. doi: 10.1212/WNL.0000000000006875. Epub 2019 Jan 9.
6
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer's disease spectrum.血浆寡聚β-淀粉样蛋白与阿尔茨海默病谱系中的疾病严重程度和脑淀粉样蛋白沉积相关。
Alzheimers Res Ther. 2024 Mar 11;16(1):55. doi: 10.1186/s13195-024-01400-3.
7
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.氟替卡匹尔PET tau蛋白结合与淀粉样蛋白负荷、临床诊断、年龄和认知之间的关系。
Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.
8
Olfactory deficits and amyloid-β burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study.阿尔茨海默病、轻度认知障碍和健康衰老患者的嗅觉缺失与淀粉样β负担:一项 PiB PET 研究。
J Alzheimers Dis. 2010;22(4):1081-7. doi: 10.3233/JAD-2010-100696.
9
Amyloid-aβ Peptide in olfactory mucosa and mesenchymal stromal cells of mild cognitive impairment and Alzheimer's disease patients.轻度认知障碍和阿尔茨海默病患者嗅黏膜和间充质基质细胞中的淀粉样β肽
Brain Pathol. 2015 Mar;25(2):136-45. doi: 10.1111/bpa.12169. Epub 2014 Sep 5.
10
Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.经正电子发射断层扫描(PET)生物标志物检测,诊断为阿尔茨海默病所致轻度认知障碍,伴有β淀粉样蛋白和神经元功能障碍。
PLoS One. 2013 Jun 14;8(6):e66877. doi: 10.1371/journal.pone.0066877. Print 2013.

引用本文的文献

1
Infections with and SARS-CoV-2 and Alzheimer's disease pathogenesis.感染与新型冠状病毒 2 型以及阿尔茨海默病发病机制。 (注:原文中“with and SARS-CoV-2”表述不太完整准确,推测可能是想说“with SARS-CoV-2”之类的,但按照要求完整翻译此句如上)
Front Aging Neurosci. 2025 Jun 13;17:1587782. doi: 10.3389/fnagi.2025.1587782. eCollection 2025.
2
Diagnosis of Anosmia in Middle Age, But Not in Older Adulthood, Increases Alzheimer Dementia Risk.中年嗅觉丧失的诊断会增加患阿尔茨海默病痴呆症的风险,但老年期嗅觉丧失则不会。
Clin Exp Otorhinolaryngol. 2025 Aug;18(3):264-270. doi: 10.21053/ceo.2024.00345. Epub 2025 Mar 17.
3
Olfactory dysfunction as potential biomarker in neurodegenerative diseases: a narrative review.

本文引用的文献

1
Lecanemab: Appropriate Use Recommendations.仑卡奈单抗:合理使用建议。
J Prev Alzheimers Dis. 2023;10(3):362-377. doi: 10.14283/jpad.2023.30.
2
Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective.《阿尔茨海默病早期 Lecanemab 的疗效:淀粉样蛋白级联假说 2.0 视角下的机制解读》。
J Alzheimers Dis. 2023;93(4):1277-1284. doi: 10.3233/JAD-230164.
3
The Amyloid Cascade Hypothesis in Alzheimer's Disease: Should We Change Our Thinking?阿尔茨海默病中的淀粉样蛋白级联假说:我们是否应该改变思路?
嗅觉功能障碍作为神经退行性疾病的潜在生物标志物:一项叙述性综述
Front Neurosci. 2025 Jan 7;18:1505029. doi: 10.3389/fnins.2024.1505029. eCollection 2024.
4
A Pilot Study of the Computerized Brief Smell Identification Test.计算机化简易嗅觉识别测试的一项初步研究。
Diagnostics (Basel). 2024 Sep 25;14(19):2121. doi: 10.3390/diagnostics14192121.
5
Olfactory deficit: a potential functional marker across the Alzheimer's disease continuum.嗅觉减退:阿尔茨海默病连续过程中的一个潜在功能标志物。
Front Neurosci. 2024 Feb 16;18:1309482. doi: 10.3389/fnins.2024.1309482. eCollection 2024.
6
Minding the Gap: Exploring Neuroinflammatory and Microglial Sex Differences in Alzheimer's Disease.关注差距:探索阿尔茨海默病中的神经炎症和小胶质细胞性别差异。
Int J Mol Sci. 2023 Dec 12;24(24):17377. doi: 10.3390/ijms242417377.
Biomolecules. 2023 Mar 1;13(3):453. doi: 10.3390/biom13030453.
4
Latest Trends in Outcome Measures in Dementia and Mild Cognitive Impairment Trials.痴呆症和轻度认知障碍试验中结局指标的最新趋势
Brain Sci. 2022 Jul 14;12(7):922. doi: 10.3390/brainsci12070922.
5
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.用于阿尔茨海默病的血液生物标志物:迈向临床应用
Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24.
6
Olfactory dysfunction in aging and neurodegenerative diseases.衰老和神经退行性疾病中的嗅觉功能障碍。
Ageing Res Rev. 2021 Sep;70:101416. doi: 10.1016/j.arr.2021.101416. Epub 2021 Jul 27.
7
Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress.阿尔茨海默病的新型生物标志物:基于N-甲基-D-天冬氨酸受体低激活和氧化应激
Clin Psychopharmacol Neurosci. 2021 Aug 31;19(3):423-433. doi: 10.9758/cpn.2021.19.3.423.
8
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.阿尔茨海默病的临床诊断:国际工作组的建议。
Lancet Neurol. 2021 Jun;20(6):484-496. doi: 10.1016/S1474-4422(21)00066-1. Epub 2021 Apr 29.
9
Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease.机器学习与新型生物标志物在阿尔茨海默病诊断中的应用。
Int J Mol Sci. 2021 Mar 9;22(5):2761. doi: 10.3390/ijms22052761.
10
Association of Odor Identification Ability With Amyloid-β and Tau Burden: A Systematic Review and Meta-Analysis.嗅觉识别能力与β-淀粉样蛋白和tau蛋白负荷的关联:一项系统评价和荟萃分析。
Front Neurosci. 2020 Nov 26;14:586330. doi: 10.3389/fnins.2020.586330. eCollection 2020.